Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 3/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719043 | 0.91 | BRAF (0.33) | MAPK1BRAFMAPK3 | |
| SCHEMBL2317228 | 0.90 | BRAF (0.33) | MAPK1NPSR1BRAFMAPK3PTGS2 | |
| SCHEMBL14108515 | 0.90 | MAPK1 (0.33) | MAPK1NPSR1BRAFMAPK3AURKA | |
| SCHEMBL2358954 | 0.89 | MAPK1 (0.37) | HCRTR2MAPK1NPSR1BRAFMAPK3 | |
| SCHEMBL2359667 | 0.88 | BRAF (0.34) | MAPK1NPSR1BRAFMAPK3PTGS2 | |
| SCHEMBL2318038 | 0.87 | HCRTR2 (0.36) | HCRTR2MAPK1BRAFMAPK3PTGS2 | |
| SCHEMBL2317938 | 0.87 | BRAF (0.33) | MAPK1BRAFMAPK3AURKAAURKB | |
| SCHEMBL2358526 | 0.86 | MAPK1 (0.33) | MAPK1NPSR1BRAFMAPK3 | |
| SCHEMBL2359767 | 0.86 | BRAF (0.33) | MAPK1NPSR1BRAFMAPK3 | |
| SCHEMBL14719372 | 0.86 | HCRTR2 (0.33) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | claimed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | claimed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | claimed |
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | disclosed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | disclosed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K15, MAP3K19, CDK3 | HCRTR2 4851/4885MAPK1 83/4885NPSR1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.